Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix vaccination with temporary JAK-inhibitor interruption in immunosuppressed inflammatory bowel disease
ISRCTN72434858Phase 4Recruiting
- Sponsor
- Imperial College London
- Start
- Jul 2026
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of Zoster vaccine recombinant, tofacitinib, upadacitinib and filgotinib in herpes zoster (HZ) (2 arms), sponsored by Imperial College London. Primary endpoint: Primary immunogenicity endpoint. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ISRCTN72434858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72434858.